Holen Sie sich die Stockscreener-App
6.43
1.53%
-0.10
Relmada Therapeutics Inc Aktie (RLMD) Neueste Nachrichten
Guidance Update: How do insiders feel about Relmada Therapeutics IncQuarterly Market Summary & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Wall Street Analysts Predict a 92.19% Upside in Relmada Therapeutics (RLMD): Here's What You Should Know - sharewise.com
Wall Street experts anticipate a potential 92.19% increase for Relmada Therapeutics (RLMD): Key Information You Need to Know - bitget.com
Portfolio Update: Should I invest in Relmada Therapeutics Inc before earningsBuy Signal & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Relmada (RLMD) Q4 2025 Earnings Call Transcript - AOL.com
Here’s what makes Mizuho bullish on Relmada Therapeutics Inc (RLMD) stock - MSN
RLMD stock surges 42% in a week: Here's what you should know - msn.com
how Fair Value analysis spotted Relmada’s 65% gain in 2024 By Investing.com - Investing.com India
how Fair Value analysis spotted Relmada’s 65% gain in 2024 - Investing.com
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Sees Large Increase in Short Interest - MarketBeat
Piper Sandler initiates coverage of Relmada Therapeutics (RLMD) with overweight recommendation - msn.com
Here’s What Makes Mizuho Bullish on Relmada Therapeutics Inc (RLMD) Stock - Insider Monkey
Relmada Therapeutics (RLMD) Gains on Positive Analyst Coverage - gurufocus.com
Relmada stock wins bullish view at Piper Sandler (RLMD:NASDAQ) - Seeking Alpha
Piper Sandler Initiates Relmada Therapeutics(RLMD.US) With Buy Rating, Announces Target Price $12 - Moomoo
Relmada Therapeutics (NASDAQ:RLMD) Earns Overweight Rating from Analysts at Piper Sandler - MarketBeat
Piper Sandler Initiates Coverage on RLMD with Overweight Rating - gurufocus.com
Relmada Therapeutics stock initiated at Overweight by Piper Sandler - Investing.com
Short Squeeze: Is Relmada Therapeutics Inc a speculative investment2026 Stock Rankings & Growth Focused Entry Reports - baoquankhu1.vn
Relmada Therapeutics Reports Strong 2025 Results, $160M Financing, and Advances NDV-01 Bladder Cancer Program to Phase 3 - Minichart
Relmada Therapeutics Charts Aggressive Path After Earnings Call - TipRanks
Relmada Highlights NDV-01 Data, Funding in 2025 Results - TipRanks
Relmada (NASDAQ: RLMD) narrows 2025 loss, funds NDV-01 Phase 3 push - Stock Titan
Relmada Therapeutics price target raised to $19 from $10 at Mizuho - TipRanks
RLMD: Mizuho Analyst Raises Price Target to $19, Maintains Outpe - GuruFocus
VR Adviser Adds Over 1 Million Savara Shares - AOL.com
Relmada Therapeutics (NASDAQ:RLMD) Price Target Raised to $19.00 - MarketBeat
Mizuho raises Relmada Therapeutics stock price target on trial data By Investing.com - Investing.com Australia
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2025 Earnings Call Transcript - Insider Monkey
Mizuho raises Relmada Therapeutics stock price target on trial data - Investing.com
Here's Why Ovid Therapeutics Stock Popped Higher Today - AOL.com
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Relmada Therapeutics Inc (RLMD) PT Raised to $19 at Mizuho - StreetInsider
Relmada Therapeutics Inc (RLMD) Q4 2025 Earnings Call Highlights: Strategic Advancements and Financial Insights - gurufocus.com
Relmada Therapeutics 2025 Annual Report: Clinical-Stage Drug Development, Regulatory Risks, and Strategic Overview - Minichart
Relmada Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Relmada Therapeutics Inc.'s 2025 Q4 Call: 12-Month Data Timing, Phase 3 Enrollment, and R&D Cost Signals Don’t Match - Bitget
Relmada (RLMD) Fourth Quarter 2025 Earnings Conference Call Transcript - Bitget
Relmada Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Relmada Therapeutics (NASDAQ:RLMD) Releases Quarterly Earnings Results, Misses Expectations By $0.13 EPS - MarketBeat
Earnings call transcript: Relmada Therapeutics Q4 2025 shows EPS miss, stock stable - Investing.com India
Transcript : Relmada Therapeutics, Inc., Q4 2025 Earnings Call, Mar 19, 2026 - marketscreener.com
RLMD: NDV-01 phase II data show 76% 12-month CR and strong safety, supporting phase III launch - TradingView
Earnings call transcript: Relmada Therapeutics Q4 2025 shows EPS miss, stock stable By Investing.com - Investing.com South Africa
Relmada Therapeutics Q4 Earnings Call Highlights - MarketBeat
RLMD: NDV-01 achieved 76% 12-month CR in NMIBC; $160M financing secures operations through 2029 - TradingView
RLMD: NDV-01 delivers high response rates in NMIBC, with Phase 3 trials and strong financial runway ahead - TradingView
RLMD: NDV-01 achieved durable, high response rates with favorable safety in high-risk NMIBC - TradingView
Relmada Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Relmada Therapeutics 10-K: $0 Revenue, $(1.45) EPS on $(57.39)M Net Loss - TradingView
RELMADA THERAPEUTICS ($RLMD) Releases Q4 2025 Earnings - quiverquant.com
RLMD: Net loss improved to $57.4M in 2025 as focus shifted to new drug candidates and cash reserves grew - TradingView
Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Relmada (NASDAQ: RLMD) pivots to NDV-01 cancer drug and sepranolone - Stock Titan
Relmada Therapeutics Q4 net loss narrows as expenses decline - TradingView
RLMD: Strong NDV-01 clinical results and $160M financing support Phase 3 launch and extended cash runway - TradingView
Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update - The Manila Times
BRIEF-Relmada Therapeutics Q4 EPS USD -0.27 - TradingView
Bladder cancer drug shows 76% response at 12 months as Relmada readies Phase 3 - Stock Titan
3.03%
2.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):